FAM
Fred Alger Management Portfolio holdings
AUM
$22.3B
1-Year Return
57.87%
This Quarter Return
+2.95%
1 Year Return
+57.87%
3 Year Return
+264.72%
5 Year Return
+406.03%
10 Year Return
+1,631.73%
AUM
$19.7B
AUM Growth
-$1.68B
(-7.8%)
Cap. Flow
-$1.18B
Cap. Flow
% of AUM
-5.96%
Top 10 Holdings %
Top 10 Hldgs %
29.74%
Holding
577
New
76
Increased
189
Reduced
196
Closed
58
Top Buys
| 1 |
Netflix
NFLX
|
$147M |
| 2 |
Eli Lilly
LLY
|
$146M |
| 3 |
Marvell Technology
MRVL
|
$142M |
| 4 |
Centene
CNC
|
$141M |
| 5 |
Amazon
AMZN
|
$103M |
Top Sells
| 1 |
Intuit
INTU
|
$158M |
| 2 |
Visa
V
|
$154M |
| 3 |
Applied Materials
AMAT
|
$141M |
| 4 |
CrowdStrike
CRWD
|
$99.3M |
| 5 |
AVLR
Avalara, Inc.
AVLR
|
$93.5M |
Sector Composition
| 1 | Technology | 28.33% |
| 2 | Healthcare | 24.22% |
| 3 | Consumer Discretionary | 14.38% |
| 4 | Industrials | 10.17% |
| 5 | Communication Services | 7.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Vinci Compass Investments Ltd. Class A Common Shares
VINP
$639M
| $416K | ﹤0.01% |
40,470
| – | – |
|
402
Ventyx Biosciences
VTYX
$180M
| $415K | ﹤0.01% |
+11,879
| New | +$415K |
|
403
Akero Therapeutics
AKRO
$3.61B
| $408K | ﹤0.01% |
+11,981
| New | +$408K |
|
404
Nuvalent
NUVL
$5.9B
| $401K | ﹤0.01% |
20,651
+14,402
| +230% | +$280K |
|
405
SOPHiA GENETICS
SOPH
$220M
| $401K | ﹤0.01% |
152,593
+35
| +0% | +$92 |
|
406
Rapid Micro Biosystems
RPID
$119M
| $400K | ﹤0.01% |
123,830
-1
| -0% | -$3 |
|
|
RNLX
407
DELISTED
Renalytix plc American Depositary Shares
RNLX
| $394K | ﹤0.01% |
307,642
+61
| +0% | +$78 |
|
408
Immunocore
IMCR
$1.84B
| $374K | ﹤0.01% |
+7,977
| New | +$374K |
|
409
Amylyx Pharmaceuticals
AMLX
$901M
| $362K | ﹤0.01% |
12,842
+7,713
| +150% | +$217K |
|
410
Cartesian Therapeutics
RNAC
$278M
| $361K | ﹤0.01% |
7,334
-40
| -0.5% | -$1.97K |
|
411
Rockwell Automation
ROK
$38.2B
| $345K | ﹤0.01% |
1,603
| – | – |
|
412
Syndax Pharmaceuticals
SNDX
$1.47B
| $327K | ﹤0.01% |
+13,618
| New | +$327K |
|
413
BioAtla
BCAB
$31.1M
| $317K | ﹤0.01% |
+41,171
| New | +$317K |
|
414
Tenet Healthcare
THC
$17.3B
| $316K | ﹤0.01% |
6,130
+2,145
| +54% | +$111K |
|
415
Okta
OKTA
$16.1B
| $313K | ﹤0.01% |
5,497
+230
| +4% | +$13.1K |
|
|
KDNY
416
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $313K | ﹤0.01% |
+15,925
| New | +$313K |
|
417
CRISPR Therapeutics
CRSP
$4.96B
| $299K | ﹤0.01% |
+4,573
| New | +$299K |
|
418
Pool Corp
POOL
$12.5B
| $297K | ﹤0.01% |
932
-31,688
| -97% | -$10.1M |
|
419
Repare Therapeutics
RPTX
$72.6M
| $295K | ﹤0.01% |
24,311
+1,539
| +7% | +$18.7K |
|
420
Allegion
ALLE
$14.7B
| $294K | ﹤0.01% |
3,277
-400
| -11% | -$35.9K |
|
421
Entrada Therapeutics
TRDA
$205M
| $283K | ﹤0.01% |
+17,955
| New | +$283K |
|
422
Levi Strauss
LEVI
$8.81B
| $266K | ﹤0.01% |
18,405
| – | – |
|
423
Biomea Fusion
BMEA
$114M
| $256K | ﹤0.01% |
+26,204
| New | +$256K |
|
424
Milestone Pharmaceuticals
MIST
$152M
| $245K | ﹤0.01% |
+26,672
| New | +$245K |
|
425
Align Technology
ALGN
$10B
| $238K | ﹤0.01% |
1,151
| – | – |
|